Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.

@article{Majzner2017AssessmentOP,
  title={Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.},
  author={Robbie G Majzner and Jason S. Simon and Joseph F. Grosso and Daniel N Martinez and Bruce R. Pawel and Mariarita R Santi and Melinda S. Merchant and Birgit Geoerger and Imene Hezam and Virginie Marty and Phillippe Vielh and Mads Daugaard and Poul H. B. Sorensen and Crystal L Mackall and John M. Maris},
  journal={Cancer},
  year={2017},
  volume={123 19},
  pages={3807-3815}
}
BACKGROUND Programmed death 1 (PD-1) signaling in the tumor microenvironment dampens immune responses to cancer, and blocking this axis induces antitumor effects in several malignancies. Clinical studies of PD-1 blockade are only now being initiated in pediatric patients, and little is known regarding programmed death-ligand 1 (PD-L1) expression in common childhood cancers. The authors characterized PD-L1 expression and tumor-associated immune cells (TAICs) (lymphocytes and macrophages) in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 10 times. VIEW TWEETS